Biomet Offers $280 Mil. For J&J’s DePuy Trauma Biz; Bid Facilitates Synthes Deal
This article was originally published in The Gray Sheet
Executive Summary
J&J expects the divestiture to reduce regulatory barriers to its pending $21 billion Synthes acquisition.